Life Sciences

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28 May 2026

Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies, today announced that the U.S. Food and...

Read more
vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty
27 May 2026

vorteX-io raises €8.5 million to make hydrological data a driver of national sovereignty

VorteX -io Raises €8.5 Million from Seventure Partners, Banque des Territoires, and Daphni to Turn Hydrological Data into a Lever for National Sovereignty and Address Global...

Read more
Microbiotica reports positive results for MB097 in advanced melanoma
18 May 2026

Microbiotica reports positive results for MB097 in advanced melanoma

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment.

Microbiotica has announced positive findings from its phase 1b MELODY‑1...

Read more
Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes
12 May 2026

Enterome presents Phase 2 indolent non-Hodgkin lymphoma data at EHA showing EO2463 induces B cell target-specific CD8 T-cell expansion correlating with clinical outcomes

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-target in vivo immune therapies shown to induce a rapid, long-lasting and...

Read more
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
15 April 2026

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013

Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting...

Read more
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
2 April 2026

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the...

Read more
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31 March 2026

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-
generation proteins, has announced a $34.2 million (€30 million) Series...

Read the press release
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10 February 2026

Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

Kainova Therapeutics (“the Company”), a key player for breakthrough treatments for patients in immuno-oncology and inflammation, today announced the successful first close...

Read more